MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
39.75
-1.19
-2.91%
After Hours: 39.75 0 0.00% 16:10 12/15 EST
OPEN
41.64
PREV CLOSE
40.94
HIGH
41.64
LOW
39.50
VOLUME
926.25K
TURNOVER
--
52 WEEK HIGH
46.01
52 WEEK LOW
14.80
MARKET CAP
3.21B
P/E (TTM)
-19.6093
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CGON last week (1208-1212)?
Weekly Report · 20h ago
CG Oncology Price Target Announced at $70.00/Share by Wedbush
Dow Jones · 4d ago
Wedbush Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $70
Benzinga · 4d ago
CG Oncology initiated with an Outperform at Wedbush
TipRanks · 4d ago
Promising Data on CG Oncology’s Cretostimogene Justifies Buy Rating
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), CG Oncology, Inc. (CGON) and Disc Medicine (IRON)
TipRanks · 12/08 13:01
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results
Simply Wall St · 12/08 12:16
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Nurix Therapeutics (NRIX)
TipRanks · 12/08 11:50
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.